Correction to: Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAdvanced Breast Cancer Therapies · Lung Cancer Research Studies · HER2/EGFR in Cancer Research
Shao Z, et al., Cancer Med. 2024 Aug;13(15):e7408. https://doi.org/10.1002/cam4.7408. PMID: 39136200; PMCID: PMC11320080
We requested post‐publication to add the following line after the first line in the acknowledgment section:
We also thank DMC chair Prof. Xichun Hu, DMC member Prof. Jin Zhang, Prof. Shusen Wang, Prof. Renbing Liu, and Prof. Chen Yao for their contributions to the trial.
We apologize for this error.